Latest Information Update: 12 Nov 2016
At a glance
- Originator Novartis
- Class Analgesics
- Mechanism of Action Cannabinoid receptor CB1 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain; Postherpetic neuralgia
Most Recent Events
- 22 Mar 2004 Phase-II clinical trials in Pain in USA (unspecified route)
- 22 Jan 2003 Phase-I clinical trials in Pain in USA (unspecified route)